Net Income Up 2.91% Gross Margin Increased 1.28%
BEIJING, March 18, 2013 (GLOBE NEWSWIRE) -- Dehaier Medical Systems Ltd. (Nasdaq:DHRM) ("Dehaier" or the "Company"), an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products, today announced its financial results for the fourth quarter and year ended December 31, 2012.
Mr. Ping Chen, Chief Executive Officer of Dehaier Medical, stated, "We are pleased with our progress in 2012 as our business strategy has proved to be the right decision for our company. We strengthened the force of our state-level medical procurement department and gained abundant experience in bidding and project implementation. In addition, we enhanced our intellectual property portfolio by obtaining copyrights for our newly-developed products and technologies. We also refined our sleep respiratory and oxygen therapy business strategies and enriched our product pipeline by becoming a distributor of GCE's efficient oxygen valve and an effective sleep diagnosis and management system to address the increasing demands of the sleep apnea and oxygen therapy market."Mr. Ping Chen continued, "Outside of China, one of our products was selected for a long-term purchasing agreement in Ukraine and Germany. Finally, we realized improved net profit and EPS by controlling our internal costs, adjusting our revenue mix of homecare products sales and medical equipment sales and streamlining the inventory and manufacturing process. We will devote much of our effort to the burgeoning sleep diagnostic and oxygen therapy markets and expect to drive a more diverse and robust revenue stream to the Company." Operating Highlights for Fiscal Year 2012
Major State-level Medical Procurement Contracts:
- In March 2012, the Company won a new bid to implement a government procurement project to provide imaging equipment for township hospitals in Xi'an, Shaanxi, China.
- In September 2012, the Company won a 3-year procurement agreement for its proprietary air compressors and customized trolleys from a major medical equipment manufacturer in Ukraine.
- In September 2012, the Company signed three medical equipment procurement agreements with Beijing's Hospitals 304 and 307, two of China's most well-known first-tier hospitals, and with Beijing Kanglian Medicines Co. for the China Development Bank Rural Medical and Health Construction Project.
- In October 2012, the Company won a government procurement contract with Xinjiang Province to distribute medical equipments to Hospitals in Xinjiang. The contract will be implemented by the end of 2012.
- In December 2012, the Company signed a medical equipment procurement agreement with Hebei province for the China Development Bank Rural Medical and Health Construction Project.
Intellectual Property Progress:
- In January 2012, the Company received Conformité Européenne (CE) certification for the sleep diagnostic devices and air compressors. The CE mark recognizes that the two products meet European Union (EU) health and safety standards and are approved for sale in the 27 member states of the EU and in the four members of the European Free Trade Association (EFTA).
- Also in March 2012, the Company obtained two software copyrights for its CPAP devices. The addition of these copyrights to our intellectual property portfolio reflects progress in our ongoing research and development efforts into the new generation of homecare CPAP devices.
- In July 2012, the Company received approval from China's State Food and Drug Administration ("SFDA") for its proprietary homecare medical CPAP device, the DHR-CPAP-C5. The certificate is valid until July 1, 2016 (subject to renewal) and allows us to sell the product in mainland China.
- Also between April and June 2012, the Company obtained software copyrights from China's National Copyright Administration for four of its proprietary technologies, including (1) Analysis and Monitoring Software of Adsorption Tower Oxygen Generation Process, (2) Dehaier Homecare CPAP Controlling Software, (3) Ventilator of CPAP Controlling Software and (4) Air Compressor Controlling Software. These copyrights have been approved for 50 years from the grant date.
- In September 2012, the Company obtained Megapixels software copyrights for its DHR C-Arm X Ray Machine. The upgraded technology can produce optimized images with minimal user involvement through its advanced imaging technology.
Distribution Authorizations Extension:
- In April 2012, the Company renewed its strategic cooperation agreement with Timesco of London Ltd. The agreement appoints Dehaier as the exclusive distributor for Timesco's CXL and Eclipse series laryngoscope products in mainland China for three years.
- In May 2012, the Company extended its exclusive distribution authorization with INTERMEDICAL ("IMD"), to distribute its RADIUS C-arm X-ray machines in mainland China. The extended term runs through 2014.
- In June 2012, the Company entered a three-year strategic mutual cooperation agreement with HEYER Medical AG ("Heyer"). According to this agreement, the Company will continue to be one of the key Chinese distributors for Heyer's anesthesia machines and the exclusive distributor of its nebulizers in China.
- In September 2012, the Company entered into a two-year distribution agreement with GCE group, a leading global compressed gas-equipment company, to become the exclusive distributor for GCE's EASE II product in Mainland China. The newly-distributed product can be widely used in many fields including disaster relief efforts, national defense, emergency rooms, ambulances, and medical institutions.
Research and Development Achievements and Company Progress:
- Also in June 2012, the Company co-developed a "High-Efficiency Oxygen Inhaler" with Dr. Ding Jianzhang of Beijing Haidian Hospital. The portable device is designed for use in homecare oxygen therapy, emergency treatment, disaster relief activities and high-altitude settings.
- In October 2012, the Company renewed its status of National High Technology Enterprises and received government subsidies of RMB118,100 for short-term bank loan interest, as a result of favorable treatment granted to High Technology Enterprises.
- In December 2012, Beijing Zhongguancun Enterprises Credit Promotion Association improved the Company's credit rating from BBB+ to A-, as a result of its improved performance of competitiveness in the industry, relatively strong enterprise system, sustainable business model and low credit risk.
- In December 2012, the Company presented its newly-developed Efficient Oxygen Supplement System ("EOS System") at the 2012 Military Surgical Symposium, held in Tianjin from November 30 to December 2, 2012. The symposium featured high level, forward-looking medical concepts and theories and best practices.
- For the years ended December 31, 2012 and 2011, our total revenues amounted to approximately $21.37 million and $21.64 million, respectively. Our net income attributable to Dehaier for the years ended December 31, 2012 and 2011 was approximately $3.21 million and $3.10 million, respectively. Net income attributable to Dehaier increased slightly on slightly decreased revenues, mainly due to the Company's operating strategy changes that reduced expenses. While we continuously developed our sales channels on traditional medical devices sales, we have also been adjusting our strategy to expand into government procurement projects and the burgeoning respiratory and oxygen homecare market.
- Our total revenues decreased by 1.24% from $21.64 million for the fiscal year ended December 31, 2011 to $21.37 million for the fiscal year ended December 31, 2012. In 2012, we continuously developed our sales channels for traditional medical devices sales. At the same time, we also began to adjust our operating strategy to expand into government procurement projects and the burgeoning respiratory and oxygen homecare market. Management believes revenues have decreased slightly in traditional device sales due to an increasingly challenging market and new competitors. Further, our government procurement efforts and homecare business are still at a relatively early stage. As a result, our overall revenues are slightly lower than in 2011.
- Our gross profit increased from $7.94 million in 2011 to $8.12 million in 2012, and our gross margin increased slightly from 36.70% in 2011 to 37.98% in 2012. Management believes the shift in the Company's revenue mix away from traditional device sales resulted in increases in gross margin and net income.
- As a result of the foregoing, we generated an operating income of approximately $4.39 million in 2012, compared to approximately $3.61 million in 2011. Operating income increased by 21.46% largely due to the decrease in selling expenses.
- As a result of the foregoing, we had net income of approximately $3.22 million in 2012, compared to approximately $3.13 million in 2011. After deduction of non-controlling interest in income, net income attributable to Dehaier was approximately $3.21 million and $3.10 million in 2012 and 2011, respectively.
|Cash and Cash Equivalents||$3.5||$3.7|
|Total Long-term Debt||0||0|
- As of December 31, 2012, we had $3.51 million cash and cash equivalents. As a result of the total cash activities, net cash decreased from $3.69 million at December 31, 2011, mainly because we invested in obtaining copyright protection for our software for our future development.
- We believe that our currently available working capital of $28.9 million including cash, should be adequate to meet our anticipated cash needs and sustain our current operations for at least 12 months.
|DEHAIER MEDICAL SYSTEMS LIMITED AND AFFILIATE|
|CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME|
|For the years ended December 31,|
|Costs of revenue||(13,254,587)||(13,696,743)|
|General and administrative expense||(2,599,368)||(2,620,845)|
|Financial expenses (including interest expense of $149,488 and $82,136)||(151,720)||(86,712)|
|Change in fair value of warrants liability||(180,192)||221,640|
|Income before provision for income tax and non-controlling interest||4,079,147||3,781,848|
|Provision for income tax||(862,795)||(656,297)|
|Non-Controlling interest in income||(10,201)||(22,431)|
|Net income attributable to Dehaier Medical Systems Limited||3,206,151||3,103,120|
|Other comprehensive income|
|Foreign currency translation adjustments||398,686||1,174,044|
|Comprehensive income attributable to the non-controlling interest||(27,173)||(85,442)|
|Comprehensive income attributable to Dehaier Medical Systems Limited||3,587,865||4,214,153|
|Earnings per share|
|Weighted average number of common shares used in computation|
|DEHAIER MEDICAL SYSTEMS LIMITED AND AFFILIATE|
|CONSOLIDATED BALANCE SHEETS|
|Cash and cash equivalents||3,505,330||3,694,486|
|-less allowance for doubtful accounts of $865,769 and $859,509||11,960,193||12,159,842|
|Other receivables, net||556,635||411,194|
|Advances to Suppliers||4,470,756||4,348,847|
|Prepayment and other current assets||4,069,975||2,365,154|
|Deferred tax asset||119,437||118,030|
|Total Current Assets||32,692,977||31,629,258|
|Property and equipment, net||2,895,523||3,348,533|
|Intangible assets, net||2,694,439||--|
|LIABILITIES AND EQUITY|
|Advances from customers||248,940||303,000|
|Accrued expenses and other current liabilities||406,452||349,158|
|Total Current Liabilities||3,840,477||4,647,701|
|Commitments and Contingency|
|Common shares, $0.002731 par value, 18,307,038 shares authorized, 4,620,000 and 4,560,000 shares issued and outstanding at December 31, 2012 and 2011, respectively||12,618||12,454|
|Additional paid in capital||13,500,847||13,281,374|
|Accumulated other comprehensive income||2,967,202||2,585,488|
|Total Dehaier Medical Systems Limited shareholders' equity||32,628,390||28,820,888|
|Total liabilities and equity||38,282,939||34,977,791|
|DEHAIER MEDICAL SYSTEMS LIMITED AND AFFILIATE|
|CONSOLIDATED STATEMENTS OF CASH FLOWS|
|For the years ended December 31,|
|Cash flows from operating activities|
|Adjustments to reconcile net income to net cash provided by (used in) operating activities|
|Stock-based compensation expense||314,479||144,453|
|Depreciation and amortization||552,086||450,518|
|Change in fair value of warrants liability||180,192||(221,640)|
|(Recovery of) Provision for doubtful accounts||(3,939)||749,280|
|Provision for doubtful accounts - other receivables||598,747||--|
|Provision for warranty reserve||--||37,303|
|Deferred tax benefit||--||(118,030)|
|Changes in assets and liabilities:|
|Decrease (Increase) in accounts receivable||344,341||(3,797,045)|
|Increase in prepayments and other current assets||(1,730,704)||(1,413,176)|
|Decrease (Increase) in other receivables||(1,617,781)||642,287|
|Decrease in inventories||931,844||842,052|
|Decrease in tax receivable||563,816||2,630,467|
|Increase in accounts payable||4,271||3,607|
|(Decrease) Increase in advances from customers||(56,965)||33,811|
|Increase in accrued expenses and other current liabilities||52,482||14,470|
|Decrease in taxes payable||(1,644,345)||(6,285,660)|
|Net cash provided by (used in) operating activities||1,704,876||(3,161,752)|
|Cash flows from investing activities|
|Capital expenditures and other additions||(11,054)||(153,061)|
|Advances to related parties||--||(2,358)|
|Net cash used in investing activities||(2,726,507)||(155,419)|
|Cash flows from financing activities|
|Proceeds from bank loan||2,373,145||1,542,680|
|Repayment of bank loan||(1,580,436)||(1,533,604)|
|Net cash provided by financing activities||792,709||9,076|
|Effect of exchange rate fluctuations on cash and cash equivalents||39,766||1,079,195|
|Net decrease in cash and cash equivalents||(189,156)||(2,228,900)|
|Cash and cash equivalents at beginning of year||3,694,486||5,923,386|
|Cash and cash equivalents at end of year||3,505,330||3,694,486|
|Supplemental cash flow information|
|Income tax paid||1,416,958||1,906,763|
CONTACT: Dehaier Medical Systems Limited Surie Liu +86 10-5166-0080 email@example.com Dehaier Medical Systems Limited Tina He +86 10-5166-0080 firstname.lastname@example.org
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV